Yanan Zhu
Stock Analyst at Wells Fargo
(3.49)
# 918
Out of 5,049 analysts
81
Total ratings
48.53%
Success rate
6.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $29.40 | +144.90% | 7 | Nov 3, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Equal-Weight | $45 → $17 | $12.84 | +32.40% | 6 | Oct 28, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $9.30 | +115.05% | 9 | Oct 23, 2025 | |
| QURE uniQure | Maintains: Overweight | $65 → $80 | $29.13 | +174.63% | 4 | Oct 2, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.96 | +35.14% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $37.59 | +19.71% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $73.67 | +11.31% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $2.39 | +401.95% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $4.48 | +78.57% | 3 | Aug 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $4 → $2.5 | $1.28 | +96.08% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.53 | +226.80% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $1.88 | +646.67% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $69.83 | +7.41% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $50 | $17.26 | +189.69% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $23.71 | +195.23% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.48 | +123.21% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $23.23 | +72.19% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $60.08 | +8.19% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.01 | +327.96% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.58 | +589.66% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.66 | +16,849.15% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $848.91 | -61.60% | 1 | Feb 2, 2021 |
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $29.40
Upside: +144.90%
Intellia Therapeutics
Oct 28, 2025
Downgrades: Equal-Weight
Price Target: $45 → $17
Current: $12.84
Upside: +32.40%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $9.30
Upside: +115.05%
uniQure
Oct 2, 2025
Maintains: Overweight
Price Target: $65 → $80
Current: $29.13
Upside: +174.63%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.96
Upside: +35.14%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $37.59
Upside: +19.71%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $73.67
Upside: +11.31%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.39
Upside: +401.95%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $4.48
Upside: +78.57%
Fate Therapeutics
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.28
Upside: +96.08%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.53
Upside: +226.80%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $1.88
Upside: +646.67%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $69.83
Upside: +7.41%
Aug 7, 2025
Maintains: Overweight
Price Target: $48 → $50
Current: $17.26
Upside: +189.69%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $23.71
Upside: +195.23%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.48
Upside: +123.21%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $23.23
Upside: +72.19%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $60.08
Upside: +8.19%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $7.01
Upside: +327.96%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.58
Upside: +589.66%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.66
Upside: +16,849.15%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $848.91
Upside: -61.60%